Drug Channels

SEPTEMBER 17, 2024

On October 8, 2024, Drug Channels Institute will release our 2024-25 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. Read on for more details. All rights reserved.

Pharmaceuticals 52

Pharmaceuticals Licensing Licensing Drugs 52

Drug Channels

JULY 23, 2024

It’s time for Drug Channels ’ annual update on pricing at the largest pharmaceutical manufacturers. Insulin has been the first to deflate—and the Humira biosimilar market may be next. Read more » © 2006-2024 HMP Omnimedia, LLC d/b/a Drug Channels Institute , an HMP Global Company. You can find links to each company’s data below.

Biosimilars 52

Biosimilars Pharmaceuticals Production Drugs 52

Drug Channels

JULY 29, 2020

My recent tweets have highlighted: VC’s pharmacy love, physicians’ biosimilar concerns, drug trend in workers’ comp, copay accumulator news, the outlook for insurance costs, remdesivir pricing, Philly pharmacies, how paid parking boosts telemedicine, and more. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc.

Pharmacy 52

Pharmacy Biosimilars Drugs Pharmaceuticals 52

Drug Channels

OCTOBER 10, 2023

I am pleased to announce our new 2023–24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors , available for purchase and immediate download. pharmaceutical distribution industry. we analyze the IRA’s likely consequences for wholesalers and the overall pharmaceutical business. and Section 6.4.3.

Pharmaceuticals 40

Pharmaceuticals Specialty Pharmacies Pharmacy Biosimilars 40

Drug Channels

SEPTEMBER 12, 2023

On October 10, 2023, Drug Channels Institute will release 2023-24 Economic Report on Pharmaceutical Wholesalers and Specialty Distributors. pharmaceutical distribution industry. Copyright © 2006-2023 Pembroke Consulting, Inc. Click here to email us if you would like to pay by corporate purchase order or check.

Pharmaceuticals 40

Pharmaceuticals Pharmacy Biosimilars Licensing 40

Drug Channels

OCTOBER 23, 2023

Copyright © 2006-2023 Pembroke Consulting, Inc. Eduardo De La Calle, Director of Regional Supply, AstraZeneca Shefali Shah, Global VP, Market Value and Commercial Effectiveness, MindMaze And more ! The content of Sponsored Posts does not necessarily reflect the views of Pembroke Consulting, Inc., Drug Channels, or any of its employees.

Pharmacy 75

Pharmacy Biosimilars Marketing Production 75

The Pharma Data

APRIL 4, 2023

Biosimilars help patients to gain broader access to effective and high-quality treatments that improve their disease therapies,” said Rebecca Guntern, Head of Region Europe, Sandoz. It has a leading global portfolio with eight marketed biosimilars and a further 15+ in various stages of development.

Biosimilars 40

Biosimilars Pharmacokinetics FDA Approval Packaging 40

Drug Channels

DECEMBER 1, 2020

During 2020, the COVID-19 pandemic disrupted every aspect of the pharmaceutical channel—and our lives. Pharmaceutical wholesalers have maintained shipments and operational capacity. Read more » Copyright © 2006-2020 Pembroke Consulting, Inc. Pharmacy and healthcare provider markets experienced unprecedented volatility.

Pharmacy 40

Pharmacy Drugs Vaccine Pharmaceuticals 40

The Pharma Data

MAY 15, 2023

Before joining Solvias Group, Karen held various senior leadership roles at Novartis, including global head investor relations from 2000 to 2006, head M&A and Executive Committee member, as well as site head for the Vaccines & Diagnostics division between 2006 and 2011. the world’s largest food company, since 2015.

Science 40

Science Doctors Government Pharmaceuticals 40

Agency IQ

AUGUST 2, 2024

and the E.C.

FDA 40

FDA Science Regulations Biosimilars 40

Agency IQ

JULY 28, 2023

A big nitrosamine deadline approaches : Unless you’ve been hiding under a rock for the last few years, you’ve probably heard about major issues that the pharmaceutical industry has been having with nitrosamine contamination. That would leave 19% of staff affected by furloughs. But despite the law’s age, it is not yet fully operational.

FDA 40

FDA Science Biosimilars Regulations 40

Drug Patent Watch

JANUARY 13, 2025

Biosimilars have emerged as a game-changing force, promising to revolutionize patient access to life-saving biologics while simultaneously reducing healthcare costs. ”[1] The global biosimilars market is experiencing exponential growth, with projections indicating it will reach $69.4 billion by 2025, growing at a CAGR of 34.2%

Biosimilars 78

Biosimilars Marketing Treatment Small Molecule 78

Drug Channels

APRIL 3, 2025

ICYMI, the largest three pharmaceutical wholesalersCardinal Health, Cencora, and McKessonare using vertical integration to build significant market positions in businesses beyond drug distribution. In the video clip below, I review the vertical integration status of the largest three pharmaceutical wholesalers, illustrated in the chart below.

Marketing 52

Marketing Pharmaceuticals Biosimilars Drugs 52

Drug Channels

FEBRUARY 4, 2025

ICYMI, the largest three pharmaceutical wholesalersCardinal Health, Cencora, and McKessonare using vertical integration to build significant market positions in businesses beyond drug distribution. In the video clip below, I review the vertical integration status of the largest three pharmaceutical wholesalers, illustrated in the chart below.

Marketing 52

Marketing Pharmaceuticals Biosimilars Drugs 52

FDA Law Blog: Biosimilars

DECEMBER 3, 2024

142, the Preserve Access to Affordable Generics and Biosimilars Act. Nevertheless, we are where we are at the moment and Congress is pressing on for passage of the Preserve Access to Affordable Generics and Biosimilars Act. Karst — On August 30, 2024, we posted on what was then the most recent version of S.

Biosimilars 80

Biosimilars Licensing Licensing Production 80